Eupraxia Pharmaceuticals (EPRX) Competitors $2.99 -0.01 (-0.47%) Closing price 01/31/2025 03:34 PM EasternExtended Trading$2.90 -0.09 (-3.01%) As of 01/31/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends EPRX vs. GLUE, KRRO, NMRA, MBX, PGEN, OLMA, CRVS, CTNM, CMRX, and LFVNShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Monte Rosa Therapeutics (GLUE), Korro Bio (KRRO), Neumora Therapeutics (NMRA), MBX Biosciences (MBX), Precigen (PGEN), Olema Pharmaceuticals (OLMA), Corvus Pharmaceuticals (CRVS), Contineum Therapeutics (CTNM), Chimerix (CMRX), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Monte Rosa Therapeutics Korro Bio Neumora Therapeutics MBX Biosciences Precigen Olema Pharmaceuticals Corvus Pharmaceuticals Contineum Therapeutics Chimerix LifeVantage Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk. Is EPRX or GLUE more profitable? Monte Rosa Therapeutics' return on equity of -62.68% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -219.64% -96.00% Monte Rosa Therapeutics N/A -62.68%-38.83% Does the media favor EPRX or GLUE? In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 2 mentions for Monte Rosa Therapeutics and 1 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.89 beat Monte Rosa Therapeutics' score of 0.44 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Eupraxia Pharmaceuticals Very Positive Monte Rosa Therapeutics Neutral Which has higher valuation and earnings, EPRX or GLUE? Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$28.22M-$0.72-4.15Monte Rosa TherapeuticsN/AN/A-$135.35M-$1.83-3.64 Do analysts rate EPRX or GLUE? Eupraxia Pharmaceuticals currently has a consensus price target of $9.00, suggesting a potential upside of 201.41%. Monte Rosa Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 110.21%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community prefer EPRX or GLUE? Monte Rosa Therapeutics received 11 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 46.67% of users gave Monte Rosa Therapeutics an outperform vote. CompanyUnderperformOutperformEupraxia PharmaceuticalsOutperform Votes3100.00% Underperform VotesNo VotesMonte Rosa TherapeuticsOutperform Votes1446.67% Underperform Votes1653.33% Do insiders & institutionals have more ownership in EPRX or GLUE? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryEupraxia Pharmaceuticals and Monte Rosa Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.03M$6.91B$5.59B$9.12BDividend YieldN/A2.90%5.31%3.99%P/E RatioN/A4.3057.1113.81Price / SalesN/A321.061,261.0581.64Price / CashN/A73.5045.9637.70Price / Book99.535.275.124.71Net Income-$28.22M$136.98M$111.17M$224.24M7 Day Performance1.91%-0.59%2.37%-0.17%1 Month Performance-5.80%0.18%3.19%0.60%1 Year PerformanceN/A7.68%24.69%20.43% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals3.6191 of 5 stars$2.99-0.5%$9.00+201.4%N/A$78.03MN/A-4.1529Positive NewsGap DownGLUEMonte Rosa Therapeutics2.5017 of 5 stars$5.66-1.7%$14.00+147.3%+25.7%$347.75MN/A-3.0990Short Interest ↑KRROKorro Bio1.8911 of 5 stars$37.00+0.1%$144.00+289.2%-32.8%$346.69MN/A0.0070News CoveragePositive NewsNMRANeumora Therapeutics4.222 of 5 stars$2.05-5.5%$16.50+704.9%-87.0%$331.20MN/A-1.10108Short Interest ↓MBXMBX BiosciencesN/A$9.89-6.2%$37.25+276.6%N/A$330.52MN/A0.0036News CoveragePGENPrecigen3.821 of 5 stars$1.11flat$6.33+470.6%-2.2%$325.09M$6.22M-2.02190Gap DownOLMAOlema Pharmaceuticals2.2341 of 5 stars$5.66+7.2%$27.00+377.0%-53.1%$324.32MN/A-2.5870Positive NewsCRVSCorvus Pharmaceuticals2.4524 of 5 stars$5.01+5.9%$12.38+147.0%+168.0%$321.93MN/A-5.3930Short Interest ↑Positive NewsCTNMContineum Therapeutics3.2561 of 5 stars$12.44-0.3%$29.25+135.1%N/A$320.68M$50M0.0031Upcoming EarningsCMRXChimerix4.1175 of 5 stars$3.55-3.0%$8.50+139.4%+320.8%$319.29M$320,000.00-3.7890Short Interest ↓News CoverageLFVNLifeVantage4.4266 of 5 stars$25.31+0.0%$30.50+20.5%+298.5%$317.01M$196.01M79.10260Upcoming Earnings Related Companies and Tools Related Companies Monte Rosa Therapeutics Competitors Korro Bio Competitors Neumora Therapeutics Competitors MBX Biosciences Competitors Precigen Competitors Olema Pharmaceuticals Competitors Corvus Pharmaceuticals Competitors Contineum Therapeutics Competitors Chimerix Competitors LifeVantage Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EPRX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
